Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond?

Journal of Addiction Medicine

Volumn 9, Issue 3, 2015, Pages 238-243

  Nunes, Edward V ^a   Krupitsky, Evgeny ^b   Ling, Walter ^c   Zummo, Jacqueline ^d   Memisoglu, Asli ^d   Silverman, Bernard L ^d   Gastfriend, David R ^e  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALKERMES INC   (United States)

^e TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

abstinence; clinical severity; extended release naltrexone; opioid dependence; predictors

Indexed keywords

NALTREXONE; PLACEBO; DELAYED RELEASE FORMULATION; NARCOTIC ANTAGONIST;

ADDICTION SEVERITY INDEX; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; EXTENDED DRUG RELEASE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OPIATE ADDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TREATMENT RESPONSE; WITHDRAWAL SYNDROME; ADMINISTRATION AND DOSAGE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; OPIOID-RELATED DISORDERS; THERAPEUTIC USE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942794962     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000125     Document Type: Article

References (37)

1. Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care 2011;17(suppl 8):S235-S248.
2. Bigelow GE, Preston KL, Schmittner J, et al. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-Abusing adults: doseeffects and time-course. Drug Alcohol Depend 2012;123:57-65.
3. Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12:657-667.
4. Carpenter KM, Jiang H, SullivanMA, et al. Betting on change:modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav 2009;23:47-55.
5. Carroll KM, Ball SA, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingencymanagement and significant other involvement. ArchGen Psychiatry 2001;58:755-761.
6. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2006;63:210-218.
7. Crevecoeur-MacPhail D. Whose mu Fared Better? The Effect of Extended Release Naltrexone on Treatment Outcomes for Opioid and Alcohol Users. Paper presented at: The 2014 Annual Addiction Health Services Research (AHSR) Conference; October 15-17, 2014; Boston, MA.
8. DeFulio A, Everly JJ, Leoutsakos JM, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial. Drug Alcohol Depend 2012;120:48-54.
9. EuroQol Group. EuroQol, a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
10. Gastfriend DR. Intramuscular extended-release naltrexone: current evidence. Ann NY Acad Sci 2011;1216:144-166.
11. Goldstein A. Heroin addiction: neurobiology, pharmacology, and policy. J Psychoactive Drugs 1991;23:123-133.
12. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: US Department of Health and Human Services, 1976. DHHS Publ No ADM 91-338
13. Hulse GK, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 2009;66:1108-1115.
14. International Harm Reduction Association. The Global State of Harm Reduction 2010: Key Issues for Broadening the Response. London, England: International Harm Reduction Association, 2010.
15. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: Ameta-Analytical review. Addiction 2006;101:491-503.
16. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2003;2: CD001333.
17. Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377:1506-1513.
18. Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep 2010;12:448-453.
19. Krupitsky EM, Blokhina EA. Long-Acting depot formulations of naltrexone for heroin dependence: A review. Curr Opin Psychiatry 2010;23: 210-214.
20. Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 2004;26:285-294.
21. Lobmaier P, Kornor H, Kunoe N, et al. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008;2:CD006140.
22. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;2:CD002209.
23. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003;2:CD002207.
24. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992;9:199-213.
25. Mercer DE, Woody GE. Therapy Manuals for Drug Addiction Series. Individual Drug Counseling. Rockville, MD: National Institutes of Health, US Department of Health and Human Services, 1999
26. Metzger DS, Navaline HA, Woody GE. Assessment of substance abuse: HIV risk assessment battery (RAB). In: Carson-DeWitt R, Macmillan-Thomson G, eds. Encyclopedia of Drugs, Alcohol, and Addictive Behavior. New York, NY: Macmillan Reference, 2001.
27. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011;4: CD001333.
28. Nunes EV, Rothenberg JL, SullivanMA, et al. Behavioral therapy to augment oral naltrexone for opioid dependence: A ceiling on effectiveness? Am J Drug Alcohol Abuse 2006;32:503-517.
29. Preston KL, Silverman K, Umbricht A, et al. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999;54:127-135.
30. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007;2:35.
31. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing selfreported alcohol consumption. In: Litten RZ, Allen JP, eds. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: The Humana Press, 1992:41-72.
32. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009;10:1727-1740.
33. Substance Abuse and Mental Health Services Administration. An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. Advisory 2012;11.
34. SullivanMA, Garawi F, Bisaga A, et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007;91:289-292.
35. Sullivan MA, Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opioid dependence: Analysis of a stage I trial. Am J Addict 2006;15:150-159.
36. Ware JE, Kosinski M, Dewey JE. How to Score Version Two of the SF-36 Health Survey. Lincoln, RI: Quality Metric, 2000.
37. Willette RE. The development of sustained action preparations of narcotic antagonists. NIDA Res Monogr 1976;9:31-34.